On 28 February 2021, the World Day of Rare Diseases was celebrated, a very significant celebration, which, since 2008, has contributed to keep the attention on rare diseases high and to “turn on the light” on them, as per the slogan chosen by UNIAMO (Federation of Associations of People with Rare Diseases of Italy).
“Covid has a thousand faces. Let’s fight them all! ” PlumeStars with the University of Ferrara to fight Covid-19
PlumeStars is pleased to annonuce that has been selected for participating at the important X-HUB TOKYO’S INBOUND PROGRAM 2021.
X-HUB TOKYO’S INBOUND PROGRAM, sponsored by the Tokyo Metropolitan Government, is an accelerator program that provides opportunities for global startups in the field of FinTech, Mobility, and Life Science to enter Tokyo market.
Read more “PlumeStars has been selected with other 41 global startups for X-HUB TOKYO’S INBOUND PROGRAM”
Prof. Paolo Colombo, CEO of PlumeStars srl, has been invited to enter in the rExpert committee of the research project called AEROPERF. The project will take place in Liège, Belgium, subsidized by the Wallon Region. The Expert Committee included Prof. Nicolas Tsapis of Paris-Sud University and Marco Laackmann of Haro Hofliger.
Read more “Prof. Paolo Colombo invited in the Expert Committee of AEROPERF research project”
We are pleased to announce that PlumeStars has received the certification “Seal of Excellence” delivered by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020.
Read more “Hyalcis’s SEAL OF EXCELLENCE certificate by the European Commission”
We are pleased to announce that the Controlled Release Society (CRS) has announced the election of Paolo Colombo, Pharm. D., Ph.D., CEO of PlumeStars, Emeritus Professor, Department of Food and Drug, University of Parma, Italy to its College of Fellows.
Read more “PAOLO COLOMBO ELECTED INTO CONTROLLED RELEASE SOCIETY (CRS) COLLEGE OF FELLOWS”
We are pleased to announce that The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Paolo Colombo, Pharm. D., Ph.D., CEO of PlumeStars, Emeritus Professor, Department of Food and Drug, University of Parma, Italy to its College of Fellows.
Read more “Paolo Colombo Inducted into Medical and Biological Engineering Institute (AIMBE)”
Prof. Paolo Colombo among the Top 60 most influential industry leaders on The Medicine Maker’s 2020 List
Paolo Colombo, Emeritus of the University of Parma and CEO of PlumeStars, has been named among the top 60 industrial leaders in The Medicine Maker’s 2020 Power List 2020.
Read more “Prof. Paolo Colombo among the Top 60 most influential industry leaders on The Medicine Maker’s 2020 List”
9-10 DECEMBER: TWO DAY SEMINAR “QUALITY BY DESIGN IN PHARMACEUTICAL DEVELOPMENT: THEORY AND CASE STUDIES”, IN COLLABORATION WITH UNIVERSITY OF PARMA
On 9th and 10 th December 2019, at the Department of Food and Drug of the University of Parma, the two days course “Quality by Design in Pharmaceutical Development. Theory and case studies”, will take place.
Read more “9-10 DECEMBER: TWO DAY SEMINAR “QUALITY BY DESIGN IN PHARMACEUTICAL DEVELOPMENT: THEORY AND CASE STUDIES”, IN COLLABORATION WITH UNIVERSITY OF PARMA”
From 3rd to 6th of November, PlumStars will participate at AAPS 2019 AAPS, an annual Conference of the American Association of Pharmaceutical Scientists that will be held at Henry B. González Convention Center, San Antonio, TX, USA.
There will be pitching, demonstrations and great presentations, with take-aways for both investors and innovation driven organizations.
Prof. Paolo Colombo (PlumeStars CEO) will present two different speeches:
- “Hyaluronic-Cisplatin Film for Implant for Malignant Mesothelioma Recurrences”.
- “Flurbiprofen powders for nose-to-brain delivery as alzheimer’s disease modifying agent”.
The first speech concerns Hyalcis exploits nanotechnology and advanced material research results to bring to market an innovative medical treatment of mesothelioma. The studies until now conducted revealed an interaction between the polymer hyaluronic acid and cisplatin that gave rise to a drug-polymer complex, lymphatically absorbed and blood distributed.
The uptake by pharmaceutical industry of the hyaluronic- cisplatin film technology studied by PlumeStars will assign a more effective cure against recurrences of this rare and very aggressive form of cancer that is difficult to diagnose and highly resistant to anticancer drugs.
Dr. Eride Quarta (PharmD; PhD Student, PlumeStars Research Leader) will present:
- “Novel Insulin Powder: bioavalability in rats”.
AAPS PharmSci 360 combines all the energy of a large scientific conference with the intimacy of a niche meeting.
Five robust tracks covering all aspects of the pharmaceutical sciences, hundreds of exhibitors with dozens of additional learning opportunities, thousands of scientific posters featuring the latest, most innovative research in the field.